Ruiz 2006.

Methods	Method of randomisation unclear
Participants	11 participants (median age 50 years; sex nm) with metastatic breast cancer treated with pegylated liposomal doxorubicin. Prior anthracycline therapy nm; prior cardiac radiotherapy possible for 4 participants (number of participants in each treatment group nm); no prior cardiac dysfunction
Interventions	Pegylated liposomal doxorubicin with a peak dose of either 50 mg/m2 or 60 mg/m2 (infusion duration nm; number of participants in each treatment group nm; cumulative anthracycline dose nm)
Outcomes	Response rate: 1/4 evaluable participants in the 50 mg/m2 group achieved a partial response (definition nm) as did 2/4 evaluable participants in the 60 mg/m2 group. PFS (definition nm): median time to progression was 104 days in the 50 mg/m2 group and 168 days in the 60 mg/m2 group. Toxicity: not presented for each treatment group separately; unclear if cardiotoxicity has been evaluated.
Notes	Not all randomised participants were evaluated. Median length of follow‐up was 9.2 months. This study has not been published in full text (29 December 2015); from the currently available data it is unclear if this study is eligible for inclusion in this review

nm: not mentioned
PFS: progression‐free survival